Global
About
Development milestones Mission&Vision Founder Research Achievement
Technology Platforms
Single domain antibody Five core technology platforms
PIPELINE
BUSINESS PARTNERSHIPS
Product Out-Licensing Co-Development
INVESTORS
CAREERS
Our Story Social Recruitment
News
Company News Media
Contact Us
Company Address Online Message
×
Pipeline

Progress and introduction
of main products

Pipeline
Precision-focused product portfolio strategy，accelerated development of competitive advantage products.
Inhaled VHH
Project
Target
Indication
Route of Administration
Clinical trial area
Pre-Clinical
Discovery
CMC
Toxicology
IND
Clinical Phase I
Clinical Phase II
Rights
LQ036
IL-4Rα
Autoimmune
EOS Asthma
Inhaled
2023 :Australia Phase I SAD completion
Global
EOS Asthma
Inhaled
March-2025 :phase IIa PoC readout, IIb trial-initiated in July 2025
Global
COPD
Inhaled
Q1 2026 CDE approved ;Q2 2026 FDA approval
Global
LQ036
More
LQ043H
TSLP
Autoimmune
Asthma
Inhaled
2024: Phase Ia SAD trial completion ,DPI (Co-D)
Global
LQ043H
More
Oral VHH
Project
Target
Indication
Route of Administration
Clinical trial area
Pre-Clinical
Discovery
CMC
Toxicology
IND
Clinical Phase I
Clinical Phase II
Rights
LQ083
TL1A
IBD
Oral
CMC, Q4 2026 IND
Global
LQ083
More
LQ087
TL1A/IL-23p19
Autoimmune
IBD, PsO
Oral
Leads optimization
Global
LQ087
More
LQ091
Undisclosed
Autoimmune
Oral
Leads optimization
Global
Bispecific VHH
Project
Target
Indication
Route of Administration
Clinical trial area
Pre-Clinical
Discovery
CMC
Toxicology
IND
Clinical Phase I
Clinical Phase II
Rights
LQ080
TL1A/IL-23p19
IBD, PsO
SC
CMC
Global
LQ080
More
LQ085
undisclosed
Immuno-Oncology
Autoimmune
SC
Leads optimization
Global